SB 49 SD1

Hawaii Senate bill in Session 2026.

Status: in_committee. Latest action: February 7, 2025.

Terminal Illness; Investigative Drug or Biological Product; Access to Care; Right-to-Try.

Bill ID HI-2026-SB-49

Session 2026

Status in_committee

Committee HHS, CPN/JDC

Senate in_committee 2025-02-07

Summary

Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions. Effective 12/31/2050. (SD1)

Sponsor

Stanley Chang

Official Source Back to Bills

Actions Timeline

Date	Event	Detail
0000-00-00	Introduced	Bill introduced
2025-02-07	Status	in_committee
2025-02-07	Latest Action	Report adopted; Passed Second Reading, as amended (SD 1) and referred to CPN/JDC.

More Bills From This Sponsor

SB 2983 SD1 HD1 CD1

Criminal Destruction of Trees; State or County Property; Misdemeanor

enacted • Senate

SB 2057 SD2 HD2 CD1

State Law Enforcement Agencies; County Law Enforcement Agencies; Law Enforcement Officials; Federal Immigration Authorities; Prohibition; Immigration Enforcement

enacted • Senate

SB 2074 SD1 HD3 CD1

Stadium Authority; Naming Rights; Stadium; Concessions; Marketing; Stadium Development Special Fund

enacted • Senate

SB 2613 SD1 HD3 CD1

DOE; BLNR; Department of Land and Natural Resources; City and County of Honolulu; County of Kauai; Public Schools; Land Transfer

enacted • Senate

SB 2272 SD1 HD2 CD1

DOH; Home Health Agencies; Licensing Inspections; CMS; Accreditation Organizations; Certification Organizations; Public Information

enacted • Senate

SB 2061 SD2 HD2 CD1

HCDA; Affordable Housing; Ninety-Nine Year Leasehold Program; Condominium Units; Owner‑Occupied Residential Use

enacted • Senate